(3-chlorophenyl)(diphenyl)methyl chloride | 59154-29-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: (3-chlorophenyl)(diphenyl)methyl chloride
• 英文别名: 3-chloro-trityl chloride；3-Chlor-tritylchlorid；(m-Chlorophenyl)-(diphenyl)-methyl chloride；1-chloro-3-[chloro(diphenyl)methyl]benzene
• CAS: 59154-29-9
• 化学式: C₁₉H₁₄Cl₂
• 分子量: 313.226
• InChiKey: JIOMOSMOFRFEGZ-UHFFFAOYSA-N

物化性质

• 熔点：
  55-57 °C
• 沸点：
  406.4±40.0 °C(Predicted)
• 密度：
  1.222±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.5
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  (3-chlorophenyl)(diphenyl)methyl chloride 在 1,4-环己二烯 、 四氯化钛 作用下， 以 二氯甲烷 为溶剂， 生成 ((3-chlorophenyl)methylene)dibenzene
  参考文献：
  名称：

  建立全面的氢化物供体能力量表

  摘要：

  从几个氢化物供体到benzhydrylium离子氢化物转移率在20℃下被测量和用于经验亲核性参数的确定Ñ和š Ñ根据线性自由能关系日志 ķ 20℃ =小号Ñ（Ñ + Ë）。ity离子对氢化物提取速率常数与根据反应性参数s N，N和E计算得出的速率常数的比较显示出合理的一致性。因此，有可能将大量关于三苯甲烷离子氢化物提取的文献数据转化为N和相应氢化物供体的s N参数，并为氢化物供体建立覆盖20个数量级以上的反应性标度。

  DOI：

  10.1002/chem.201202839
• 作为产物：
  描述：

  3-氯苯甲酸乙酯 在 苯 作用下， 生成 (3-chlorophenyl)(diphenyl)methyl chloride
  参考文献：
  名称：

  Organizational Buying and Advertising Agency-Client Relationships in China

  摘要：

  The 1980s and 1990s have seen the development of an interesting, diverse, and relevant body of literature on the advertising agency-client relationship. In recent times, an area of focus has been the application of organizational buying behavior principles to companies that are purchasing advertising services from advertising agencies. However, little is known about the application of such theories in the context of a developing country. After examining the literature relating to China's advertising industry and the application of organizational buying behavior principles in the advertising industry, this article reports on a survey of 200 firms in Shanghai. The results unexpectedly show that advertising agency power in the campaign development process is not related to the nature of the advertising task (new task, modified rebuy, straight rebuy) at hand. In addition, bottom-up processes give agencies the weakest pourer, and the client buying process is dominated by marketers, the salesforce, and public relations, with top managers the primary deciders.

  DOI：

  10.1080/00913367.2001.10673638

文献信息

• [EN] INHIBITOR-FUNCTIONALIZED ULTRASMALL NANOPARTICLES AND METHODS THEREOF<br/>[FR] NANOPARTICULES ULTRA-PETITES FONCTIONNALISÉES PAR UN INHIBITEUR ET MÉTHODES ASSOCIÉES
  申请人：MEMORIAL SLOAN KETTERING CANCER CENTER

  公开号：WO2018102372A1

  公开（公告）日：2018-06-07

  Described herein are novel conjugates containing an inhibitor (e.g., a PSMA inhibitor, e.g., a gastrin-releasing peptide receptor inhibitor) and metal chelator that are covalently attached to a macromolecule (e.g., a nanoparticle, a polymer, a protein). Such conjugates exhibit distinct properties over the free, unbound inhibitor/chelator construct.

  本文描述了一种新颖的结合物，其中包含一个抑制剂（例如，PSMA抑制剂，例如，胃泌素释放肽受体抑制剂）和金属螯合剂，它们以共价键连接到大分子（例如，纳米颗粒，聚合物，蛋白质）上。这种结合物在自由的未结合抑制剂/螯合剂构造体上表现出独特的特性。
• N-trityl-imidazoles as plant fungicides
  申请人：Bayer Aktiengesellschaft

  公开号：US03934022A1

  公开（公告）日：1976-01-20

  Plant fungicidal compositions are produced which comprise an amount of a compound of the formula: ##EQU1## wherein R is alkyl of 1 to 3 carbon atoms, sufficient to be effective for killing, combatting or controlling plant fungi, in combination with a solid or liquid diluent or carrier. Methods for killing, combatting or controlling fungal diseases in plants comprise applying to the fungi or to the plant to be protected an effective or toxic amount of the above compound.

  生产了植物杀菌组合物，其中包括公式如下的化合物的数量：##EQU1## 其中R是1至3个碳原子的烷基，足以有效地杀死、对抗或控制植物真菌，与固体或液体稀释剂或载体结合使用。杀灭、对抗或控制植物真菌病的方法包括向真菌或欲保护的植物施加上述化合物的有效或有毒量。
• COMBINATORIAL ROSAMINE LIBRARY TO DETECT CELL-STATE SWITCHING
  申请人：CHANG Young-Tae

  公开号：US20090227467A1

  公开（公告）日：2009-09-10

  The present invention relates to the use of rosamine derivative compounds, as described herein, in detecting differentiated forms of a cell type of interest in a sample and in screening for compounds which inhibit differentiation of the cell type of interest. The candidate compound has the following structure:

  本发明涉及使用如下所述的罗萨明衍生物化合物在样本中检测感兴趣的细胞类型的分化形式，并筛选抑制该细胞类型分化的化合物。候选化合物具有以下结构：
• PRODRUG COMPRISING A DRUG LINKER CONJUGATE
  申请人：Cleemann Felix

  公开号：US20110053848A1

  公开（公告）日：2011-03-03

  The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising a drug linker conjugate D-L, wherein -D is an amine containing biologically active moiety; and -L is a non-biologically active linker moiety -L 1 represented by formula (I), wherein the dashed line indicates the attachment to the amine of the biologically active moiety and wherein R 1 , R 1a , R 2 , R 2a , R 3 , R 3a , X, X 1 , X 2 , X 3 have the meaning as indicated in the description and the claims and wherein L 1 is substituted with one to four groups L 2 -Z and optionally further substituted, provided that the hydrogen marked with the asterisk in formula (I) is not replaced by a substituent; wherein L 2 is a single chemical bond or a spacer; and Z is a carrier group. The invention also relates to A-L, wherein A is a leaving group, pharmaceutical composition comprising said prodrugs and their use as medicaments.

  本发明涉及一种前药或其药学上可接受的盐，包括药物连接物D-L，其中-D是含有生物活性基团的胺基；而-L是非生物活性的连接基团-L1，由公式（I）表示，其中虚线表示连接到生物活性基团的胺基，其中R1、R1a、R2、R2a、R3、R3a、X、X1、X2、X3在说明书和权利要求中具有所示的含义，而L1用一到四个L2-Z基团取代并可选择进一步取代，前提是在公式（I）中标记为星号的氢未被取代；其中L2是单个化学键或间隔物；而Z是载体基团。本发明还涉及A-L，其中A是离去基团，以及包括所述前药的药物组合物及其作为药物的用途。
• Prodrug comprising a drug linker conjugate
  申请人：Ascendis Pharma A/S

  公开号：EP2596805A1

  公开（公告）日：2013-05-29

  The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising a drug linker conjugate D-L, wherein -D is an amine containing biologically active moiety; and -L is a non-biologically active linker moiety -L1 represented by formula (I), wherein the dashed line indicates the attachment to the amine of the biologically active moiety and wherein R1, R1a, R2, R2a, R3, R3a, X, X1, X2, X3 have the meaning as indicated in the description and the claims and wherein L1 is substituted with one to four groups L2-Z and optionally further substituted, provided that the hydrogen marked with the asterisk in formula (I) is not replaced by a substituent; wherein L2 is a single chemical bond or a spacer; and Z is a carrier group and wherein D-H is a polypeptide selected from the group of polypeptides consisting of exendins, glucagon, glucagon-like peptides and insulins. The invention also relates pharmaceutical composition comprising said prodrugs and their use as medicaments.

  本发明涉及一种原药或其药学上可接受的盐，包括药物连接体共轭物 D-L，其中 -D是含有生物活性分子的胺；和 -L是 由式（I）表示的非生物活性连接体分子-L1、 其中虚线表示生物活性分子与胺的连接，其中 R1、R1a、R2、R2a、R3、R3a、X、X1、X2、X3 的含义如说明书和权利要求书中所述，其中 L1 被一至四个基团 L2-Z 取代，并可选择进一步取代，条件是式（I）中标有星号的氢不被取代基取代；其中 L2 是单个化学键或间隔物；Z 是载体基团，D-H 是选自由外泌肽、胰高血糖素、胰高血糖素样肽和胰岛素组成的多肽组的多肽。本发明还涉及包含上述原药的药物组合物及其作为药物的用途。